Exchange: NASDAQ·Updated 07:34 PM EDT
ZURA logo

ZURAZura Bio Ltd - Ordinary Shares - Class A

$5.59
$0.42
(7.99%)
Today
Closed $5.68
$0.09
(1.58%)
After Hours
EarningsAug 13
Mkt Cap$499.69M
Vol619,762.00
News
all
press releases
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio's Lead Therapy
William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-dollar potential in autoimmune disease.read more...
Benzinga
More News
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced several tibulizumab program updates. Zura...
Business Wire
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Limited (Nasdaq: ZURA) (Zura or the Company), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious...
Business Wire
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and...
Business Wire
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and...
Business Wire
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Limited (Nasdaq: ZURA) (Zura or the Company), a clinicalstage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious...
Business Wire
Zura Bio (ZURA) to Release Earnings on Thursday
Zura Bio (NASDAQ:ZURA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-zura-bio-limited-stock...
MarketBeat
Zura Bio (NASDAQ:ZURA) Shares Down 5.3% - Time to Sell?
Zura Bio (NASDAQ:ZURA) Shares Down 5.3% - Here's What Happened...
MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Analysts
Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat.com reports. One...
MarketBeat
Zura Bio (NASDAQ:ZURA) Shares Down 6.5% - Here's What Happened
Zura Bio (NASDAQ:ZURA) Shares Down 6.5% - Here's What Happened...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.